Effectiveness of Ciprofloxacin and Levofloxacin in treatment of Pseudomonas Aeruginosa infection
Abstract
Background: Pseudomonas aeruginosa is the most troublesome and feared pathogen in medical field. It is the sixth most common cause of hospital-acquired infections and the cause of ventilator-associated pneumonia. The most common multidrugresistant gram-negative pathogen in Ventilated Assisted Patient. In our study in 100 patients culture and sensitivity report only 46% were sensitive to oral treatment while 54% of the pseudomonas were resistant to ciprofloxacin and 34% sensitive and 66% resistant to levofloxacin. Objective: To find out resistance of pseudomonas to oral medication. Material and Methods: A cross-sectional study, conducted in Saidu Group of Teaching Hospital from January 2018 to July 2019. ). 100 patient samples (tracheal aspirate, bronchial washing, sputum, pus, urine and blood) were cultured for pseudomonas and its sensitivity to oral medication ciprofloxacin and levofloxacin was recorded. Results: Sensitivity to 46% were samples was observed to oral treatment while 54% of the pseudomonas were resistant to ciprofloxacin and 34% sensitive and 66% resistant to levofloxacin respectively. Conclusion: It was found that 54% pseudomonas were resistant to Ciprofloxacin and 66% resistant to levofloxacin. So we should always consider for combination therapy.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 100 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.